A review assembles 25 years of work on lithium as a possible disease-modifying agent in neurodegeneration. The mechanistic argument is that lithium does not target one pathology: it induces the anti-apoptotic protein Bcl-2, enhances brain-derived neurotrophic factor signalling, inhibits glycogen synthase kinase-3 beta, stabilises mitochondrial function and reduces oxidative stress. Human magnetic resonance spectroscopy has shown raised N-acetylaspartate, consistent with better neuronal viability, and structural imaging has shown preserved grey matter in hippocampal and corticolimbic regions.
The dose is the interesting part. The neurotrophic effects described appear at around 0.3 mM, well below the 0.6 to 1.0 mM used in bipolar disorder, which is also below the range where kidney and thyroid toxicity dominate the risk-benefit conversation. Epidemiological studies have linked cumulative lithium exposure with lower dementia risk, and early randomised trials in mild cognitive impairment have suggested cognitive stabilisation and favourable tau biomarker changes at these low doses. A newer suggestion that lithium acts as a physiological trace element awaits independent replication.
The authors' conclusion is a call for a prospective trial of low-dose lithium orotate, not a recommendation to start one. That distinction needs holding, because the argument has an obvious appeal in India and other low- and middle-income settings - the authors say so explicitly - where an inexpensive, familiar, off-patent drug would matter far more than an infusion. An accessible intervention that has not been shown to work is still an intervention that has not been shown to work, and lithium orotate is sold as a supplement in some markets, with no dose standardisation and no monitoring attached.
- Do not start lithium for mild cognitive impairment outside a trial; the randomised evidence is early and small.
- Distinguish lithium orotate sold as a supplement from prescribed lithium carbonate - dose and quality are not comparable.
- Where a patient is already on lithium for bipolar disorder, this is not a reason to change the dose either way.
- Continue standard monitoring of kidney and thyroid function; the low-dose safety argument is theoretical here.
- Note that the epidemiological signal comes from people prescribed lithium for psychiatric illness, who differ from the general population in many ways.
The statistics, in plain English
This is a narrative review, so it has selected and interpreted rather than pooled, and no effect estimate is offered. The epidemiological association between lithium exposure and lower dementia risk comes from observational data in people prescribed it for bipolar disorder - a group whose dementia risk, survival and healthcare contact all differ from the general population, in directions that adjustment handles poorly. Biomarker changes and cognitive stabilisation in early trials are encouraging surrogates, not demonstrated clinical benefit.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free